In ovarian cancer, where the rate of somatic mutation is higher compared to the other cancers, PARPi have shown efficacy in patients carrying mutations of BRCA1/2, either germline or somatic, but also in wild-type BRCA1/2 [52]. This evidence concerns the gene BRCA1 and ovarian cancer.